New England Journal of Medicine Publishes Results of Breakthrough Clinical Trial Using Immunotherapy to Treat Early-Stage Esophageal Cancers

The results of a study published today in The New England Journal of Medicine found that the immunotherapy drug, if used following neoadjuvant chemoradiation therapy and surgical resection for early-stage esophageal or gastroesophageal junction cancers, can significantly prolong disease-free survival and reduce risk of disease recurrence.